FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Comparision between Tatva Chintan Pharma IPO and Windlas Biotech IPO.
Tatva Chintan Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Windlas Biotech IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.
Tatva Chintan Pharma IPO | Windlas Biotech IPO | |
---|---|---|
Logo | ||
Issue Category | Mainline | Mainline |
Issue Type | IPO | IPO |
Process Type | Book Built Issue | Book Built Issue |
Listing At | BSE, NSE | BSE, NSE |
Lead Managers | ICICI Securities Limited Jm Financial Limited |
Dam Capital Advisors Ltd (Formerly Idfc Securities Ltd) Iifl Securities Ltd SBI Capital Markets Limited |
Registrar | Link Intime India Private Ltd | Link Intime India Private Ltd |
Market Maker | ||
DRHP | DRHP | DRHP |
RHP | RHP | RHP |
Anchor Investor | ||
IPO Allotment URL | IPO Allotment URL | IPO Allotment URL |
The total issue size of Tatva Chintan Pharma IPO is up to ₹500.00 Cr whereas the issue size of the Windlas Biotech IPO is up to ₹401.54 Cr. The final issue price of Tatva Chintan Pharma IPO is ₹1,083.00 per share and of Windlas Biotech IPO is ₹460.00 per share.
Tatva Chintan Pharma IPO | Windlas Biotech IPO | |
---|---|---|
Face Value | ₹10 per share | ₹5 per share |
Issue Price (Lower) | ₹1,073.00 per share | ₹448.00 per share |
Issue Price (Upper) | ₹1,083.00 per share | ₹460.00 per share |
Issue Price (Final) | ₹1,083.00 per share | ₹460.00 per share |
Discount (Retail) | ||
Discount (Employee) | ||
Market Lot Size | 13 shares | 30 shares |
Fresh Issue Size | ||
Fresh Issue Size (Amount) | up to ₹225.00 Cr | up to ₹165.00 Cr |
OFS Issue Size | 51,42,067 shares | |
OFS Issue Size (Amount) | up to ₹275.00 Cr | up to ₹236.54 Cr |
Issue Size Total | ||
Issue Size Total (Amount) | up to ₹500.00 Cr | up to ₹401.54 Cr |
Tatva Chintan Pharma IPO opens on Jul 16, 2021, while Windlas Biotech IPO opens on Aug 04, 2021. The closing date of Tatva Chintan Pharma IPO and Windlas Biotech IPO is Jul 20, 2021, and Aug 06, 2021, respectively.
Tatva Chintan Pharma IPO | Windlas Biotech IPO | |
---|---|---|
Anchor Bid Date | ||
Issue Open | Jul 16, 2021 | Aug 04, 2021 |
Issue Close | Jul 20, 2021 | Aug 06, 2021 |
Basis Of Allotment (Tentative) | Jul 26, 2021 | Aug 11, 2021 |
Initiation of Refunds (Tentative) | Jul 27, 2021 | Aug 12, 2021 |
Credit of Share (Tentative) | Jul 28, 2021 | Aug 13, 2021 |
Listing date (Tentative) | Jul 29, 2021 | Aug 16, 2021 |
Anchor Lockin End date 1 | Aug 25, 2021 | Sep 10, 2021 |
Anchor Lockin End date 2 | Oct 24, 2021 | Nov 09, 2021 |
Tatva Chintan Pharma IPO P/E ratio is , as compared to Windlas Biotech IPO P/E ratio of .
Tatva Chintan Pharma IPO | Windlas Biotech IPO | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial |
|
|
||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Pre-Issue) | 100% | 78% | ||||||||||||||||||||||||||||||||||||||||||||
Promoter Shareholding (Post-Issue) | 79.17% | 65.16% | ||||||||||||||||||||||||||||||||||||||||||||
P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||
Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||
ROE | ||||||||||||||||||||||||||||||||||||||||||||||
ROCE | ||||||||||||||||||||||||||||||||||||||||||||||
Debt/Equity | ||||||||||||||||||||||||||||||||||||||||||||||
EPS | ||||||||||||||||||||||||||||||||||||||||||||||
RoNW |
In the Tatva Chintan Pharma IPO retail investors (RII) are offered 16,30,941 shares while in Windlas Biotech IPO retail investors are offered 16,30,941 shares. Qualified institutional buyers (QIB) are offered 9,31,966 shares in Tatva Chintan Pharma IPO and 17,23,700 shares in Windlas Biotech IPO.
Tatva Chintan Pharma IPO | Windlas Biotech IPO | |
---|---|---|
Anchor Investor Reserveration | ||
Market Maker Reserveration | ||
QIB | 9,31,966 shares | 17,23,700 shares |
NII | 6,98,975 shares | 13,23,766 shares |
RII | 16,30,941 shares | 30,88,786 shares |
Employee | 0 shares | 0 shares |
Others | ||
Total | 32,61,882 shares | 61,36,252 shares |
Tatva Chintan Pharma IPO subscribed 180.36x in total, whereas Windlas Biotech IPO subscribed 22.44x.
Tatva Chintan Pharma IPO | Windlas Biotech IPO | |
---|---|---|
QIB (times) | 185.23x | 24.40x |
NII (times) | 512.22x | 15.73x |
Big NII (times) | ||
Small NII (times) | ||
RII (times) | 35.35x | 24.22x |
Employee (times) | ||
Other (times) | ||
Total (times) | 180.36x | 22.44x |
Add a public comment...
Rs 0 Account Opening Fee
Free Eq Delivery & MF
Flat ₹20 Per Trade in F&O
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|